Mounjaro®
Starting from £179.99/mo
Start journey Learn moreSome people taking Wegovy notice that food tastes different — blander, less appealing, or occasionally unpleasant — within weeks of starting treatment. This is not imagined: taste changes are a recognised side effect of semaglutide, documented in trial data and reported consistently by patients. They are generally mild and tend to shift as the body adjusts, but they are worth understanding before you begin. Wegovy is a prescription-only medicine, so whether it is right for you is a question a prescriber settles after reviewing your full clinical picture, not something you can self-assess from a symptom list alone.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The published evidence base for semaglutide's effect on taste perception comes from multiple directions. The STEP 1 trial (68 weeks, 2.4 mg semaglutide versus placebo in adults with obesity, published in the New England Journal of Medicine) documented gastrointestinal side effects as the most common treatment-related events. Within that category, dysgeusia (the medical term for a distorted or altered sense of taste) appeared as a reported adverse event, alongside nausea, vomiting and constipation. It was not among the most frequent complaints, but it was present at a meaningful rate in the active treatment group and not the placebo group, which points clearly to semaglutide as the cause rather than coincidence.
The NHS medicines page for semaglutide lists taste changes as a recognised side effect. Regulators and prescribers classify this in the same family as other GI-related effects: the medicine alters the speed at which the stomach empties and changes signalling in the gut and brain, and both of those processes touch how flavour is experienced. It is biologically coherent, not anecdotal.
Separately, a small but consistent group of patients describe a metallic or otherwise unpleasant taste in the mouth, which is distinct from food simply tasting dull. This tends to be reported more often in the first weeks of a new dose. It is uncomfortable but not dangerous. If it persists beyond a few weeks at a stable dose, raise it with your prescriber rather than stopping treatment abruptly.
GLP-1 receptors are distributed not just in the gut and pancreas but throughout the central nervous system, including areas that govern appetite, reward and sensory processing. Semaglutide, as a GLP-1 receptor agonist, binds these receptors broadly. The result is not only reduced hunger but a quietening of the brain's reward response to food, the anticipation of a meal, the pleasure of the first bite, the pull towards highly palatable foods. Many patients describe this as food simply becoming less interesting rather than tasting outright bad.
This is connected to how Wegovy affects overall taste perception at a neurological level, and it explains why the change often feels qualitative rather than purely sensory: the food itself has not changed, but the response to it has. For most people this is actually part of how the medicine supports weight loss, the automatic reach for snacks loses its appeal. For some, though, it extends to meals they previously enjoyed, which can affect nutritional intake if it reduces eating too broadly.
Protein intake in particular deserves attention during this period. If food aversion is reducing the variety of what you eat, maintaining adequate protein helps preserve lean muscle mass alongside any fat loss. A prescriber or dietitian can advise on practical strategies; this is not something to calibrate alone.
For many patients, the sharpest taste disruption corresponds to dose increases. The titration schedule for Wegovy moves upward in steps, and the body's adjustment period at each rung tends to bring GI symptoms, including taste changes, to the fore before they settle. Once a dose has been stable for several weeks, many people find their relationship with food normalises somewhat, different from before treatment, but not distressing.
There are reasons to contact your prescriber sooner rather than later. If altered taste is making it difficult to eat adequate meals, if it is causing significant distress, or if it is accompanied by other symptoms such as persistent nausea or severe stomach pain, a clinical conversation is the right step. You can also explore how lasting these taste changes tend to be and what patients typically report over a full course of treatment. The same conversation is relevant to anyone considering the oral formulation, semaglutide delivered by tablet rather than injection presents the GI profile slightly differently, and taste effects may vary accordingly.
If you are weighing up the full cost of Wegovy treatment alongside potential side effects, factoring in the value of ongoing prescriber support makes sense. Access to a clinician who can adjust your plan if side effects become a barrier is part of what legitimate private treatment includes, not an optional extra.
There is no single fix, but there are approaches that consistently help. Eating smaller amounts more frequently tends to work better than sitting in front of a large meal that has lost its appeal. Cold or room-temperature food often has less of the aroma that can trigger nausea and the accompanying flavour blunting. Mild flavours (plain proteins, cooked vegetables, simple grains) tend to be better tolerated than heavily seasoned dishes, which can feel overwhelming when GI sensitivity is high.
Staying well hydrated matters too. Dehydration amplifies the dull or metallic quality that some patients notice, and thirst is sometimes masked during treatment because appetite and thirst signals are partly linked. A small practical note: if you are managing a busy stretch (a holiday week, or orders that need to align with your delivery schedule) plan your doses and meals around a stable routine rather than disrupted ones, since irregular eating patterns tend to make GI side effects, including taste changes, more noticeable.
The broader picture of taste changes across semaglutide treatments is something our clinical team keeps a close eye on, because it sits at the intersection of tolerability and effectiveness. If side effects are shaping your experience in ways you did not expect, a prescriber review is the right place to start, not a wait-and-see approach on your own.
If you have questions about whether Wegovy is suitable for your situation, or if taste changes are making you reconsider your current treatment, speak to our prescribers for a same-day clinical review. You can also read more about Wegovy and how it works or browse common questions about treatment before you decide.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.